UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) June 29, 2005

                               SWISS MEDICA, INC.
             (Exact name of registrant as specified in its charter)

         Delaware                    000-09489                 98-0355519
(State or other jurisdiction        (Commission               (IRS Employer
      of incorporation)             File Number)            Identification No.)

       53 Yonge Street, 3rd Floor                           M5E 1J3
        Toronto, Ontario, Canada
 (Address of principal executive offices)                  (Zip Code)

        Registrant's telephone number, including area code (416) 868-0202

--------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

      This  Form  8-K and  other  reports  filed  by  Swiss  Medica,  Inc.  (the
"Registrant"  or the  "Company")  from  time to time  with  the  Securities  and
Exchange  Commission   (collectively  the  "Filings")  contain  forward  looking
statements  and  information  that are based upon  beliefs  of, and  information
currently  available  to, the  Registrant's  management as well as estimates and
assumptions  made by the Registrant's  management.  When used in the Filings the
words "anticipate",  "believe", "estimate", "expect", "future", "intend", "plan"
or the  negative if these terms and  similar  expressions  as they relate to the
Registrant or the Registrant's  management  identify forward looking statements.
Such  statements  reflect the current  view of the  Registrant  with  respect to
future  events and are subject to risks,  uncertainties,  assumptions  and other
factors  relating  to the  Registrant's  industry,  operations  and  results  of
operations and any businesses that may be acquired by the Registrant. Should one
or more of these risks or  uncertainties  materialize,  or should the underlying
assumptions prove incorrect,  actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or planned.

      Item 5.02  Departure  of  Directors  or  Principal  Officers;  Election of
Directors; Appointment of Principal Officers.

      (a)   Resignation or removal of directors as a result of  disagreement  or
            removal for cause.

            None

      (b)   Termination of certain officers; resignation or removal of directors
            other than as a result of disagreement or removal for cause.

            None.

      (c)   Appointment of new officers or directors.

            On June 24, 2005, the Board  appointed Mr. Charles Orr to serve as a
      director of the Registrant. On June 29, 2005, Mr. Orr accepted the Board's
      offer. Under the offer letter which is attached to this Agreement, Mr. Orr
      will  receive  150,000  shares of  Registrant  common  stock and a monthly
      retainer of $3,000.00.

            From June 1993 through  September  2000, Mr. Orr served as President
      and CEO, Shaklee Corporation. From February 1994 through September 2001 he
      was a director of Provident  Mutual Life Insurance  Company and has been a
      director of The Direct Selling  Education  Foundation  since June 2001. He
      has also been a director of Herbalife  (NYSE:  HLF) since August 2002. Mr.
      Orr holds an M.B.A.  from the  University  of  Connecticut  and a B.A.  in
      Psychology from Wesleyan University.

            There is no  family  relationship  between  any of our  officers  or
      directors  and our proposed  officers and  director.  There are no orders,
      judgments,  or decrees of any governmental agency or administrator,  or of
      any court of competent jurisdiction,  revoking or suspending for cause any
      license, permit or other authority to engage in the securities business or
      in the  sale  of a  particular  security  or  temporarily  or  permanently
      restraining  any  of  our  officers  or  directors  from  engaging  in  or
      continuing  any conduct,  practice or employment  in  connection  with the
      purchase or sale of securities, or convicting such person of any felony or
      misdemeanor involving a security, or any aspect of the securities business
      or of theft or of any felony.  Nor are any of the officers or directors of
      any corporation or entity affiliated with us so enjoined.

      Item 9. Financial Statements and Exhibits

      (a)   Financial Statements of Businesses Acquired.

      Not applicable.

      (b)   Pro Forma Financial Information

      Not applicable

<PAGE>

      (c)   Exhibits.

      Exh. No.          Description

      10.1              Offer letter to Charles Orr

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                  SWISS MEDICA, INC.
                                                   (Registrant)

Date: July 8, 2005
                                               /s/ Bruce Fairbairn
                                       Bruce Fairbairn, Chief Financial Officer
{"company-data": {"conformed-name": "SWISS MEDICA INC", "cik": "0000318245", "assigned-sic": "2834", "irs-number": "980355519", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09489", "film-number": "05946540"}, "business-address": {"street1": "53 YONGE STREET, 3RD FLOOR", "street2": "TORONTO", "city": "ONTARIO, CANADA", "state": "A1", "zip": "M5E 1J3", "phone": "416-657-4134"}, "mail-address": {"street1": "53 YONGE STREET, 3RD FLOOR", "street2": "TORONTO", "city": "ONTARIO, CANADA", "state": "A1", "zip": "M5E 1J3"}, "former-company": [{"former-conformed-name": "SWISS MEDIA INC", "date-changed": "20030702"}, {"former-conformed-name": "GLOBAL PATH INC", "date-changed": "20010814"}, {"former-conformed-name": "YOURNET INC/", "date-changed": "19991108"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) June 29, 2005

                               SWISS MEDICA, INC.
             (Exact name of registrant as specified in its charter)

         Delaware                    000-09489                 98-0355519
(State or other jurisdiction        (Commission               (IRS Employer
      of incorporation)             File Number)            Identification No.)

       53 Yonge Street, 3rd Floor                           M5E 1J3
        Toronto, Ontario, Canada
 (Address of principal executive offices)                  (Zip Code)

        Registrant's telephone number, including area code (416) 868-0202

--------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))
This  Form  8-K and  other  reports  filed  by  Swiss  Medica,  Inc.  (the
"Registrant"  or the  "Company")  from  time to time  with  the  Securities  and
Exchange  Commission   (collectively  the  "Filings")  contain  forward  looking
statements  and  information  that are based upon  beliefs  of, and  information
currently  available  to, the  Registrant's  management as well as estimates and
assumptions  made by the Registrant's  management.  When used in the Filings the
words "anticipate",  "believe", "estimate", "expect", "future", "intend", "plan"
or the  negative if these terms and  similar  expressions  as they relate to the
Registrant or the Registrant's  management  identify forward looking statements.
Such  statements  reflect the current  view of the  Registrant  with  respect to
future  events and are subject to risks,  uncertainties,  assumptions  and other
factors  relating  to the  Registrant's  industry,  operations  and  results  of
operations and any businesses that may be acquired by the Registrant. Should one
or more of these risks or  uncertainties  materialize,  or should the underlying
assumptions prove incorrect,  actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or planned.

      Item 5.02  Departure  of  Directors  or  Principal  Officers;  Election of
Directors; Appointment of Principal Officers.

      (a)   Resignation or removal of directors as a result of  disagreement  or
            removal for cause.

            None

      (b)   Termination of certain officers; resignation or removal of directors
            other than as a result of disagreement or removal for cause.

            None.

      (c)   Appointment of new officers or directors.

            On June 24, 2005, the Board  appointed Mr. Charles Orr to serve as a
      director of the Registrant. On June 29, 2005, Mr. Orr accepted the Board's
      offer. Under the offer letter which is attached to this Agreement, Mr. Orr
      will  receive  150,000  shares of  Registrant  common  stock and a monthly
      retainer of $3,000.00.

            From June 1993 through  September  2000, Mr. Orr served as President
      and CEO, Shaklee Corporation. From February 1994 through September 2001 he
      was a director of Provident  Mutual Life Insurance  Company and has been a
      director of The Direct Selling  Education  Foundation  since June 2001. He
      has also been a director of Herbalife  (NYSE:  HLF) since August 2002. Mr.
      Orr holds an M.B.A.  from the  University  of  Connecticut  and a B.A.  in
      Psychology from Wesleyan University.

            There is no  family  relationship  between  any of our  officers  or
      directors  and our proposed  officers and  director.  There are no orders,
      judgments,  or decrees of any governmental agency or administrator,  or of
      any court of competent jurisdiction,  revoking or suspending for cause any
      license, permit or other authority to engage in the securities business or
      in the  sale  of a  particular  security  or  temporarily  or  permanently
      restraining  any  of  our  officers  or  directors  from  engaging  in  or
      continuing  any conduct,  practice or employment  in  connection  with the
      purchase or sale of securities, or convicting such person of any felony or
      misdemeanor involving a security, or any aspect of the securities business
      or of theft or of any felony.  Nor are any of the officers or directors of
      any corporation or entity affiliated with us so enjoined.

      Item 9. Financial Statements and Exhibits

      (a)   Financial Statements of Businesses Acquired.

      Not applicable.

      (b)   Pro Forma Financial Information

      Not applicable
(c)   Exhibits.

      Exh. No.          Description

      10.1              Offer letter to Charles Orr

                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                  SWISS MEDICA, INC.
                                                   (Registrant)

Date: July 8, 2005
                                               /s/ Bruce Fairbairn
                                       Bruce Fairbairn, Chief Financial Officer